Completed PHASE2 INTERVENTIONAL 3-arm NCT06942299

A Study of AK0529 in Adults Patients Hospitalized With RSV Infection

A Randomized, Double-blind, Placebo-controlled Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Multiple Doses AK0529 in Adult Hospitalized Subjects With Respiratory Syncytial Virus Infection

Sponsor: Shanghai Ark Biopharmaceutical Co., Ltd.

Conditions Respiratory Syncytial Virus Infections

Interventions AK0529 Placebo

Updated 2 times since 2025 Last updated: Apr 16, 2025 Started: Jul 20, 2023 Primary completion: Jun 28, 2024 Completion: Jun 28, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06942299, this PHASE2 trial focuses on Respiratory Syncytial Virus Infections and remains completed. Sponsored by Shanghai Ark Biopharmaceutical Co., Ltd., it has been updated 2 times since 2023, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

2 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
May 2025 — Sep 2025 [monthly]

Completed PHASE2

First recorded

Jul 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai Ark Biopharmaceutical Co., Ltd.

Data source: Shanghai Ark Biopharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Changchun, China , Changzhou, China , Chengdu, China , Fuzhou, China , Guangzhou, China , Guiyang, China , Hangzhou, China , Harbin, China , Hefei, China and 25 more locations